{"url_path":"/sec/grtx/8-k/2026-05-19/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1563577/0001193125-26-230711-index.html","accession_number":"0001193125-26-230711","cik":"0001563577","ticker":"GRTX","issuer_name":"Galera Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1563577/0001193125-26-230711-index.html","primary_entity_key":"0001563577","primary_entity_name":"Galera Therapeutics, Inc."},"word_count":205,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nOn May 15, 2026, Galera Therapeutics, Inc. (the “Company”) converted the remaining 42,839.11 shares of the Company’s Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (“Series B Preferred Stock”), into 42,839,103 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), pursuant to and in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock, as amended (the “Certificate of Designation”). No fractional shares of Common Stock were issued in connection with the mandatory conversion; in lieu of any fractional shares, the Company will pay each holder an amount in cash equal to the trading value of such fractional shares as of the close of business on the date of the conversion in accordance with the Certificate of Designation. Following the conversion, no shares of Series B Preferred Stock remain issued and outstanding.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nGALERA THERAPEUTICS, INC.\n\nDate: May 19, 2026\n \n\n \nBy:\n \n\n/s/ J. Mel Sorensen, M.D.\n\n \n\n \n\n \nJ. Mel Sorensen, M.D.\n\n \n\n \n\n \nPresident and Chief Executive Officer"}